Basic information Safety Related Supplier

ChemicalBook Product Catalog Indolidan

1/1

Indolidan NEW

$96.00 1mg

$233.00 5mg

$353.00 10mg

Min. Order
Purity99.69%
Cas No100643-96-7
Supply Ability10g
Update time2026-04-14

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Indolidan
CAS No	100643-96-7
EC-No
Min. Order
Purity	99.69%
Supply Ability	10g
Release date	2026/04/14

Product Introduction

Bioactivity

Name	Indolidan
Description	Indolidan (LY 195115) induces cardiovascular and adrenal hyperplastic lesions in Fischer 344 rats. Indolidan increases the risk of cardiovascular disease.
In vivo	Male and female Fischer 344 rats were treated with the positive inotropic agents, isomazole or indolidan, in the diet for 104 weeks. The doses were 0.0, 11.5, 23.5, or 48.0 mg/kg and 0.0, 0.12, 0.40, or 1.3 mg/kg, respectively. Only 17% of the males treated with 48.0 mg/kg isomazole survived the duration of the study. The male component of the indolidan study was terminated at 22 months, with only 18% of the high-dose males surviving. Sixty-five percent of the males treated with 48.0 mg/kg isomazole and 70% of the males treated with 1.3 mg/kg indolidan were found to have severe periarteritis, often with thrombi located mainly in the mesenteric arteries. Fifty-four percent of the male rats treated with 48.0 mg/kg isomazole and 55% of the male rats treated with 1.3 mg/kg indolidan died from cardiovascular disease compared to 1-2% among the control males. Animals in the low- and middle-dose groups of both studies had a lower incidence of cardiovascular disease than did those in the high-dose group. Additional lesions associated with the long-term administration of both drugs were markedly increased incidence of adrenal medullary proliferative lesions (both hyperplasia and pheochromocytomas) and increased incidence of chronic progressive glomerulonephrosis. These lesions, like those in the cardiovascular system, occurred in a dose-dependent manner and were more frequent in males than in females.[5]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 5.63 mg/mL (21.88 mM), Sonication is recommended.
Keywords	LY-195115 \| LY195115 \| Indolidan
Related Compound Libraries	Bioactive Compound Library \| ReFRAME Related Library \| Bioactive Compounds Library Max

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy